No Data
Behind the Hong Kong stock CXO's sideways oscillation, foreign investors continue to sell while domestic investors accelerate their entrance.
Recently, the public fund medical hold positions data for Q3 2024 has been gradually disclosed, with a noticeable increase in CXO positions. Additionally, the Hong Kong Stock Connect funds have significantly bought CXO symbol stocks in the past 60 days, reflecting the current optimistic attitude of domestic funds towards the subsequent rebound of the CXO sector.
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Express News | Hong Kong pharmaceutical stocks strengthened, with Innovent Bio rising more than 4%.
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
Asymchem Laboratories (06821) has canceled some of its fundraising special accounts.
Asymchem Laboratories (06821) released a notice, considering that the raised funds in the special account for some fundraising projects have...
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
No Data
No Data